Biopharma company Ocean Biomedical (NASDAQ: OCEA) on Tuesday said its scientific co-founder Dr. Jack Elias has been issued a broad patent for
Ocean Biomedical (OCEA) announces patent award for novel cancer immunotherapy treatment
Categories
pharmaceuticals
Ocean Biomedical announces private placement of $25 mln convertible notes
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said it has entered into a private placement pursuant to a securities purchase
MEDS Earnings: Trxade Health’s net loss narrows in Q1 2023; revenue down 31%
Trxade Health, Inc. (NASDAQ: MEDS), a leading health service IT company, reported a decrease in revenues for the first quarter of fiscal
Catalyst Pharmaceuticals Inc (CPRX) Q1 2023 Earnings Call Transcript
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Q1 2023 Earnings Call dated May. 11, 2023. Corporate Participants: Alicia Grande -- Vice President, Chief Financial Officer and Treasurer
Jazz Pharmaceuticals PLC (JAZZ) Q1 2023 Earnings Call Transcript
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Q1 2023 Earnings Call dated May. 10, 2023. Corporate Participants: Andrea Flynn -- Vice President and Head, Investor Relations Bruce
A snapshot of McKesson Corporation’s Q4 2023 earnings
Healthcare service provider McKesson Corporation (NYSE: MCK) announced financial results for the fourth quarter of 2023, reporting a 4% increase in revenues.
ANI Pharmaceuticals Inc (ANIP) Q1 2023 Earnings Call Transcript
ANI Pharmaceuticals Inc (NASDAQ:ANIP) Q1 2023 Earnings Call dated May. 08, 2023. Corporate Participants: Judy DiClemente -- Investor Relations Nikhil Lalwani -- Chief Executive Officer Stephen
Earnings: Regeneron Pharmaceuticals (REGN) Q1 profit falls; revenue up 7%
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Thursday reported a decline in adjusted earnings for the first quarter of 2023, despite an increase
Zoetis Inc (ZTS) Q1 2023 Earnings Call Transcript
Zoetis Inc (NYSE:ZTS) Q1 2023 Earnings Call dated May. 04, 2023 Corporate Participants: Steve Frank -- Vice President of Investor Relations Kristin
Key highlights from Moderna’s (MRNA) Q1 2023 earnings results
Moderna, Inc. (NASDAQ: MRNA) reported first quarter 2023 earnings results today. Total revenue was $1.9 billion, compared to $6.1 billion in the
Regeneron Pharmaceuticals Inc (REGN) Q1 2023 Earnings Call Transcript
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q1 2023 Earnings Call dated May. 04, 2023 Corporate Participants: Ryan Crowe — Vice President, Investor Relations Leonard S.
Pfizer (PFE): Declines in COVID-19 products expected to drag down overall revenue in 2023
Shares of Pfizer Inc. (NYSE: PFE) were down on Tuesday despite the company delivering better-than-expected results for the first quarter of 2023.
A snapshot of AmerisourceBergen’s Q2 2023 earnings results
Pharmaceutical solutions provider AmerisourceBergen Corporation (NYSE: ABC) reported higher revenues and adjusted earnings for the second quarter of 2023. Second-quarter revenue increased
PFE Earnings: All you need to know about Pfizer’s Q1 2023 earnings results
Pfizer Inc. (NYSE: PFE) reported first quarter 2023 earnings results today. Revenues declined 29% year-over-year to $18.3 billion. Reported net income fell
A snapshot of Stryker’s (SYX) Q1 2023 financial performance
Medical technology company Stryker Corporation (NYSE: SYK) announced operating results for the first quarter of 2023, reporting higher sales and profit. First-quarter
VRTX Earnings: A snapshot of Vertex Pharmaceuticals’ Q1 2023 results
Healthcare firm Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) on Monday reported a decline in adjusted earnings for the first quarter, despite an increase in
AMGN Earnings: Everything you need to know about Amgen’s Q1 results
Amgen Inc. (NASDAQ: AMGN) has reported lower revenues and adjusted earnings for the first quarter of 2023. The biotechnology firm also provided
Gilead Sciences (GILD) Earnings: 1Q23 Key Numbers
Gilead Sciences, Inc. (NASDAQ: GILD) reported total revenue of $6.4 billion for the first quarter of 2023, which was down 4% year-over-year.
Eli Lilly and Company (LLY) Q1 2023 Earnings Call Transcript
Eli Lilly and Company (NYSE: LLY) Q1 2023 earnings call dated Apr. 27, 2023 Corporate Participants: Joe Fletcher -- Senior Vice President of Investor
Bristol-Myers Squibb (BMY) reports higher Q1 profit; revenue down 3%
Biotechnology company Bristol Myers Squibb (NYSE: BMY) said its first-quarter adjusted earnings increased modestly, despite a decline in revenues. Net income attributable
MRK Earnings: Highlights of Merck’s Q1 2023 financial results
Pharma firm Merck & Co., Inc. (NYSE: MRK) on Thursday reported lower earnings for the first quarter of 2023, due to a sharp